Advanced Search

Study Preview



Study Title and Description

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Author Kumada H., Chayama K., Rodrigues L., Suzuki F., Ikeda K., Toyoda H., Sato K., Karino Y., Matsuzaki Y., Kioka K., Setze C., Pilot-Matias T., Patwardhan M., Vilchez RA., Burroughs M., Redman R.
Country Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
Year 2015
Numbers Pubmed ID: 26147154

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.